6-甲基-5,6,7,8-四氢喹啉 | 52601-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-甲基-5,6,7,8-四氢喹啉
• 英文名称: 6-methyl-5,6,7,8-tetrahydroquinoline
• 英文别名: 6-methyl-5,6,7,8-tetrahydro-quinoline；6-Methyl-5,6,7,8-tetrahydro-chinolin；5,6,7,8-Tetrahydro-6-methylchinolin；6-Methyl-5,6,7,8-tetrahydrochinolin
• CAS: 52601-65-7
• 化学式: C₁₀H₁₃N
• 分子量: 147.22
• InChiKey: AXVNAAQHRKISQI-UHFFFAOYSA-N

物化性质

• 沸点：
  231.6±9.0 °C(Predicted)
• 密度：
  0.984±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-甲基-5,6,7,8-四氢喹啉 在 乙醇 、 sodium 作用下， 生成 6-methyl-decahydro-quinoline
  参考文献：
  名称：

  Yamaguchi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1926, # 533, p. 56

  摘要：

  DOI：
• 作为产物：
  描述：

  4-methylcyclohexanone oxime O-allyl ether 反应 40.0h， 以40%的产率得到6-甲基-5,6,7,8-四氢喹啉
  参考文献：
  名称：

  Koyama, Junko; Sugita, Teruyo; Suzuta, Yukio, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 8, p. 2601 - 2606

  摘要：

  DOI：

文献信息

• GLYCINE COMPOUND
  申请人：Yoshihara Kousei

  公开号：US20120184520A1

  公开（公告）日：2012-07-19

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

  本发明提供了一种化合物，该化合物可用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 本发明的解决方案是，本发明者对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，并且对于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，具有用处，从而完成了本发明。本发明还涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐以及赋形剂。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson H. John

  公开号：US20070105866A1

  公开（公告）日：2007-05-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。
• Single-Site Cobalt Catalysts at New Zr₈(μ₂-O)₈(μ₂-OH)₄ Metal-Organic Framework Nodes for Highly Active Hydrogenation of Alkenes, Imines, Carbonyls, and Heterocycles
  作者：Pengfei Ji、Kuntal Manna、Zekai Lin、Ania Urban、Francis X. Greene、Guangxu Lan、Wenbin Lin

  DOI：10.1021/jacs.6b06759

  日期：2016.9.21

  We report here the synthesis of robust and porous metal-organic frameworks (MOFs), M-MTBC (M = Zr or Hf), constructed from the tetrahedral linker methane-tetrakis(p-biphenylcarboxylate) (MTBC) and two types of secondary building units (SBUs): cubic M8(μ2-O)8(μ2-OH)4 and octahedral M6(μ3-O)4(μ3-OH)4. While the M6-SBU is isostructural with the 12-connected octahedral SBUs of UiO-type MOFs, the M8-SBU

  我们在此报告了由四面体连接子甲烷-四(对联苯羧酸盐) (MTBC) 和两种类型的二次构建构成的坚固且多孔的金属有机框架 (MOF)、M-MTBC (M = Zr 或 Hf) 的合成单位 (SBU)：立方 M8(μ2-O)8(μ2-OH)4 和八面体 M6(μ3-O)4(μ3-OH)4。虽然 M6-SBU 与 UiO 型 MOF 的 12 个连接八面体 SBU 具有同构，但 M8-SBU 由八个 M(IV) 离子以立方方式由八个 μ2-氧代和四个 μ2-OH 基团连接而成。Zr-MTBC SBU 用 CoCl2 金属化，然后用 NaBEt3H 处理，提供了高活性和可重复使用的固体 Zr-MTBC-CoH 催化剂，用于烯烃、亚胺、羰基和杂环的氢化。Zr-MTBC-CoH 对一系列官能团的耐受性令人印象深刻，并且在三取代和四取代烯烃的氢化中显示出高活性，TON > 8000 用于氢化 2,3-二
• STABILIZATION OF ACTIVE METAL CATALYSTS AT METAL-ORGANIC FRAMEWORK NODES FOR HIGHLY EFFICIENT ORGANIC TRANSFORMATIONS
  申请人：The University of Chicago

  公开号：US20180361370A1

  公开（公告）日：2018-12-20

  Metal-organic framework (MOFs) compositions based on post¬synthetic metalation of secondary building unit (SBU) terminal or bridging OH or OH 2 groups with metal precursors or other post-synthetic manipulations are described. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations, including the regioselective boryiation and siiylation of benzyiic C—H bonds, the hydrogenation of aikenes, imines, carbonyls, nitroarenes, and heterocycles, hydroboration, hydrophosphination, and cyclization reactions. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

  基于后合成金属化的次级构建单元（SBU）端部或桥接的OH或OH2基团与金属前体或其他后合成操作的金属有机框架（MOFs）组成物被描述。这些MOFs提供了一系列多功能的可回收和可重复使用的单位固体催化剂，用于催化各种不对称有机转化，包括对苯基C—H键的区域选择性硼化和硅基化，烯烃、亚胺、醛酮、硝基芳烃和杂环化合物的加氢，氢硼化，氢磷化和环化反应。这些固体催化剂也可以集成到流动反应器或超临界流体反应器中。
• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130369A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。